Eli Lilly (LLY) stock vs the S&P 500 and pharmaceutical stocks
As of 12 October 2026, Eli Lilly (LLY) is trailing both the S&P 500 and pharmaceutical stocks as a group (PPH) over the past three months.
Where Eli Lilly stands now
As of 12 October 2026, Eli Lilly had a good month against the S&P 500 after a weaker quarter. One month alone does not make a trend.
Inside its group, LLY is catching up: ahead of pharmaceutical stocks (PPH) over the past month, still behind over three months. As a group, pharmaceutical stocks are trailing the S&P 500 right now. Stock and group are both under pressure.
Eli Lilly is 20.9% of PPH, a weight large enough to drive the fund. It sits in 3 of the sector and theme funds Zensei tracks. The thing to watch is the past month: a turn against the market usually shows there first.
Eli Lilly competitors and peers
The largest other holdings of VanEck Pharmaceutical ETF (PPH), by weight in the fund, with their plain return over the past month.
Is Eli Lilly in the S&P 500?
As of 12 October 2026, Eli Lilly is in the S&P 500. Its sector fund, Healthcare (XLV), holds it at 15.5% weight.
Every stock in one of the 11 S&P 500 sector funds is in the index. See Healthcare Stocks (XLV)
Eli Lilly ETF: the funds that hold LLY
3 funds that Zensei tracks hold LLY. The main sector is the fund Zensei groups it with. The other funds follow by weight.
LLY stock performance: 1-month, 3-month and 1-year vs the S&P 500
Eli Lilly and the S&P 500 (SPY) side by side, over each window Zensei tracks.
Prices as of · computed from daily adjusted closes · how we measure
LLY against pharmaceutical stocks, in depth
See the size of the gap between Eli Lilly and pharmaceutical stocks (PPH) over every window, its momentum and its relative strength, and where it sits among pharmaceutical stocks.
See the full analysisEli Lilly stock: common questions
Who are Eli Lilly's competitors?
As of 12 October 2026, the largest other holdings of VanEck Pharmaceutical ETF (PPH) by weight are Merck & Co Inc (MRK), Novo Nordisk (NVO), Pfizer (PFE), McKesson Corp (MCK), Bristol-Myers Squibb Co (BMY). These are the stocks Eli Lilly sits next to among pharmaceutical stocks.
Which ETFs hold Eli Lilly?
As of 12 October 2026, 3 funds that Zensei tracks hold LLY. Zensei groups it with pharmaceutical stocks in VanEck Pharmaceutical ETF (PPH), where its weight is 20.9%. It is also in Health Care Select Sector SPDR (XLV, 15.5%), SPDR S&P 1500 Momentum Tilt ETF (MMTM, 2.1%).
Is Eli Lilly in the S&P 500?
As of 12 October 2026, Eli Lilly is in the S&P 500. Its sector fund, Healthcare (XLV), holds it at 15.5% weight.
What sector is Eli Lilly in?
As of 12 October 2026, Zensei groups Eli Lilly with pharmaceutical stocks (PPH, its primary fund). In the S&P 500, it is in the Healthcare sector fund (XLV). It is also in momentum stocks (MMTM).
Is Eli Lilly stock beating the S&P 500?
As of 12 October 2026, Eli Lilly (LLY) is up 5.9% over the past month. The S&P 500 is up 2.1% over the same month. Over three months, the stock is up 0.2% and the S&P 500 is up 4.1%.
Is Eli Lilly doing better than other pharmaceutical stocks?
As of 12 October 2026, Eli Lilly (LLY) is behind pharmaceutical stocks as a group (PPH) over the past three months. Zensei Edge shows the size of the gap, its momentum and its relative strength.
Recent changes
- ·First tracked: trailing the market and pharmaceutical stocks
Track Eli Lilly against pharmaceutical stocks and the market
Zensei Edge maps 100+ sectors and themes against the S&P 500, with each stock inside them measured against its group.